



Godavari Biorefineries Ltd

Dated: February 13 , 2026

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

The Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street
Mumbai-400001

Script Symbol: GODAVARIB

Script Code:544279

Dear Sir / Madam,

Sub: Press Release

Pursuant to regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, please find enclosed the press release issued by the Company related to the financial results of the Company for the quarter and Nine Months ended December 31, 2025.

This is for your information and records.

Thanking you,
Yours faithfully

For Godavari Biorefineries Limited

Manoj Jain Digitally signed
by MANOJ JAIN
Date: 2026.02.13
19:36:52 +05'30'
MANOJ JAIN
Company Secretary & Compliance Officer
Membership No. F-7998

Godavari Biorefineries Limited Reports Q3 & 9M FY26 Results Operating Leverage Drives Profitability and Improved Margins

Mumbai, 13th February 2026 – Godavari Biorefineries Ltd., one of the largest producers of ethanol and a pioneer in manufacturing bio-based specialty chemicals in India, announced its Financial Results for the quarter and nine months ended on **Dec 31, 2025**.

Q3 FY26 Financial Performance Snapshot

(Consolidated)



Key Financial Highlights (Consolidated)

Particulars (Rs. Cr)	Q3 FY26	Q3 FY25	Y-o-Y	9M FY26	9M FY25
Total Income	461.9	450.8	+2.5%	1,430.2	1,298.2
EBITDA [^]	45.1	39.7	+13.8%	47.2	(1.4)
EBITDA Margin (%)	9.8%	8.8%	+97 bps	3.3%	(0.1%)
PBT*	21.4	8.5	+152.2%	(31.2)	(97.3)
PBT Margin (%)*	4.6%	1.9%	+275 bps	(2.2%)	(7.5%)


[^] EBITDA Includes Other Income

* PBT and PBT margins for Q3 FY26 and Q2 FY26 are reported before exceptional items. In Q3 FY26, exceptional expense of ₹7.9 crore arose from the implementation of new labor laws. In Q2 FY26, the Company recognized an exceptional expense of ₹26.7 crore related to additional harvesting charges for the 2023-24 sugar season, in line with industry practice to remain competitive.

Segment Highlights

EBITDA (Rs. Cr)	Q3 FY26	Q3 FY25	Y-o-Y	9M FY26	9M FY25
Bio Based Chemicals	10.9	6.2	+76.7%	38.2	24.3
Ethanol	4.2	9.6	(56.6%)	22.0	18.1
Sugar & Cogeneration	32.1	25.1	+28.1%	(8.5)	(40.5)

Segment Revenue Mix



Commenting on the Results, Shri Samir Somaiya, CMD said,

“Q3 FY26 marked a quarter of significantly improved profitability, driven by operating leverage and disciplined execution. EBITDA grew approximately 14% year-on-year to ₹45.1 crore, while PBT before exceptional items surged 152% year-on-year to ₹21.4 crore. Our margins also expanded meaningfully as we focus more on high-margin segments, reinforcing the company’s strategic direction.

Finance costs for the quarter declined by 46% year-on-year, in line with our strategy to improve cash flows to fuel growth. The Bio-based Chemicals segment continued to support profitability, with specialty chemicals contributing 62% of the basket in 9M FY26, and we expect this share to rise further as we scale high-value offerings.

A key highlight during the period was the grant of a U.S. patent for our novel anti-cancer molecule targeting triple-negative breast cancer, underscoring the strength of our R&D capabilities and commitment to innovation-led growth. In parallel, our DME-to-CO₂ technology initiative is progressing well, with pilot plant activities underway.

We recently collaborated with [Synthomer](#), to develop bio-based alternatives to fossil-based monomers. Through this collaboration, Synthomer is commercialising bio-based butyl acrylate using GBL’s bio-based butanol, accelerating the industry’s transition to sustainable raw materials and reflecting our continued focus on sustainability, green chemistry, and next-generation energy solutions.

We are also encouraged by strong traction in our consumer segment, with our Jivana brand crossing the ₹100 crore revenue milestone in the first nine months of FY26, reinforcing our strategy to scale the retail platform alongside our industrial businesses. Our fungible grain-based ethanol capacity will be commissioned in Q1 FY27, positioning us to benefit from the restoration of the ethanol blending program and incremental demand from maize-based capacities.

These initiatives, along with ongoing debottlenecking and investments in technology, are strengthening our ability to manage seasonality while improving efficiency. Overall, our continued focus on high-potential bio-based specialty chemicals, capacity optimization, and sustainability-led innovation positions us well to drive long-term growth and value creation.”

About Godavari Biorefineries Ltd

Godavari Biorefineries Ltd is one of the largest producers of ethanol and a pioneer in manufacturing bio-based specialty chemicals in India. It’s diversified product portfolio comprises bio-based chemicals, sugar, rectified spirits, ethanol, other grades of alcohol and power. It is the only company in India to have such a vast portfolio of bio-based products.

Company	Investor Relations: MUFG Intime India Pvt. Ltd.
Name: Mr. Ashish Sinha – AGM IR & Finance	Name: Ms. Prachi Ambre / Mr. Irfan Raeen
Email: investorrelations@somaiya.com	Email: prachi.ambre@in.mpms.mufg.com / irfan.raeen@in.mpms.mufg.com
CIN: L67120MH1956PLC009707	Tel : +91 83559 85370 / +91 97737 78669
https://godavaribiorefineries.com/	https://in.mpms.mufg.com/

Safe Harbor

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. Past performance also should not be simply extrapolated into the future. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.